Clinical trials
Brain Tumor, Recurrent clinical trials
Below are recruiting brain tumor, recurrent clinical trials, each written for real people, not researchers. We’re tracking 132 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06126276RecruitingPhase 2
Testing neratinib with or without palbociclib for HER2+ solid tumors
This trial tests two targeted drugs—neratinib alone or with palbociclib—for people with HER2-positive solid tumors (other than breast cancer) that have returned or not gone away. The goal is to see if blocking HER2 and CDK4/6 can shrink or slow the tumor.
Birmingham, AlabamaAges 18 years+ - NCT07698899RecruitingPhase 1
Study of a new treatment for childhood brain and CNS cancers
This trial tests a radioactive drug (177Lu-DTPA-Omburtamab) given directly into the fluid around the brain for children and teens with certain brain cancers or cancers that have spread to the central nervous system. It aims to see if this treatment is safe and effective for tumors that have come back or not responded to other therapies.
Basking Ridge, New JerseyAges 3–22 - NCT05892744RecruitingPhase 4
Testing brain scans to help choose depression treatment
This trial studies how brain signals measured by MRI and EEG may help doctors choose the best treatment for depression. It focuses on people with early-onset, long-lasting or recurring major depression, and tests whether these “brain biomarkers” track with treatment choice and response.
Austin, TexasAges 18–65 - NCT07668869Recruiting
Electric fields with targeted radiation vs. alone for recurrent brain cancer
This trial tests whether adding a precise, MRI-guided radiation treatment to tumor-treating electric fields (TTFields) can help people with recurrent glioblastoma. You may qualify if your tumor has come back 1 to 3 times after standard therapy and you haven't had certain prior treatments.
BydgoszczAges 18 years+ - NCT04070040RecruitingPhase 2
Camrelizumab for returning brain lymphoma after prior treatment
This trial studies camrelizumab (an immune medicine) for primary CNS lymphoma that has come back after standard treatment. It aims to shrink the lymphoma seen on MRI and help control the disease with a new immune-based approach.
BeijingAges 18 years+ - NCT06856213RecruitingPhase 2
Cetuximab with or without weekly paclitaxel for head and neck cancer
This study tests whether adding the chemotherapy drug paclitaxel (Taxol) to the targeted therapy cetuximab (Erbitux) is more effective than cetuximab alone for head and neck cancer that has progressed after initial immunotherapy and chemotherapy. Researchers want to see if the combination can help shrink tumors or slow the disease.
Santiago de Compostela, A CoruñaAges 18 years+ - NCT04870944RecruitingPhase 1/Phase 2
CBL0137 for children with advanced solid or brain tumors
This early-phase study tests CBL0137 in children and teens whose cancer has come back or is not responding to treatment. It is also for some specific hard-to-treat brain tumors, to see if the drug is safe and can work against the cancer.
Birmingham, AlabamaAges 1–21 - NCT04055649RecruitingPhase 2
Test of ONC201 and weekly paclitaxel for platinum-resistant ovarian cancer
This Phase 2 study tests whether ONC201 given with weekly paclitaxel can control platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It may help by shrinking tumors or slowing growth in people whose cancer has progressed after platinum chemotherapy.
Detroit, MichiganAges 18 years+ - NCT04519151RecruitingPhase 2
Pembrolizumab plus lenvatinib for ovarian cancer that returned
This Phase 2 trial tests whether pembrolizumab plus lenvatinib can shrink ovarian cancer that has come back after platinum chemotherapy. You may be eligible if your cancer returned after a certain “time off” from prior treatment and you meet key health and safety requirements.
Ramat GanAges 18 years+ - NCT06896110Enrolling by invitationPhase 1
Spinal chemo and immunotherapy for recurrent high-grade glioma
This trial tests a combination of two drugs—azacitidine and nivolumab—given directly into the spinal fluid for people whose high-grade glioma has come back after initial treatment. The goal is to see if this approach can safely target the tumor and slow its growth.
Iowa City, IowaAges 13 years+ - NCT06047379RecruitingPhase 1/Phase 2
Testing NEO212 for brain tumors and metastases
This trial tests a new drug called NEO212 for people with certain brain tumors (like astrocytoma or glioblastoma) or cancer that has spread to the brain from other parts of the body. The goal is to see if it is safe and if it can help shrink or control the tumors.
Beverly Hills, CaliforniaAges 18 years+ - NCT03609112Recruiting
Study brain and thinking risks in children with solid tumors
This study looks at how cancer treatment may affect children’s thinking and brain health. It may help doctors better understand risks so they can monitor and support learning and memory during and after treatment.
Villejuif, Val De MarneAges Any age
Hear when a new Brain Tumor, Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for brain tumor, recurrent?
- Yes. Clin2 currently lists 132 recruiting brain tumor, recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a brain tumor, recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a brain tumor, recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.